{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/get-your-renal-impairment-study-enrolled#webpage",
"url": "https://www.fortrea.com/insights/get-your-renal-impairment-study-enrolled",
"name": "Get Your Renal Impairment Study Enrolled",
"description": "This Fortrea article examines the challenges and opportunities associated with enrolling patients into renal impairment studies, a critical component of clinical pharmacology and drug development programs. Renal impairment studies are often required to evaluate how reduced kidney function affects the pharmacokinetics, metabolism, and disposition of investigational therapies, helping sponsors generate data that support regulatory decision-making and product labeling. However, identifying and recruiting participants across different levels of renal function can create significant operational challenges that affect study timelines and execution. The article explores strategies for improving patient identification, recruitment planning, enrollment efficiency, and study design considerations that can help sponsors successfully conduct renal impairment studies while meeting clinical development objectives and regulatory expectations. By combining clinical pharmacology expertise with effective operational execution, sponsors can improve enrollment performance, accelerate study completion, and generate the evidence needed to support drug development programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Get Your Renal Impairment Study Enrolled",
"item": "https://www.fortrea.com/insights/get-your-renal-impairment-study-enrolled"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry - as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/get-your-renal-impairment-study-enrolled#article",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/get-your-renal-impairment-study-enrolled#webpage"
},
"headline": "Renal Impairment Studies: Improving Patient Enrollment and Recruitment for Clinical Pharmacology Research | Fortrea Article",
"description": "This Fortrea article examines the challenges and opportunities associated with enrolling patients into renal impairment studies, a critical component of clinical pharmacology and drug development programs. Renal impairment studies are often required to evaluate how reduced kidney function affects the pharmacokinetics, metabolism, and disposition of investigational therapies, helping sponsors generate data that support regulatory decision-making and product labeling. However, identifying and recruiting participants across different levels of renal function can create significant operational challenges that affect study timelines and execution. The article explores strategies for improving patient identification, recruitment planning, enrollment efficiency, and study design considerations that can help sponsors successfully conduct renal impairment studies while meeting clinical development objectives and regulatory expectations. By combining clinical pharmacology expertise with effective operational execution, sponsors can improve enrollment performance, accelerate study completion, and generate the evidence needed to support drug development programs.",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-04-14",
"dateModified": "2026-04-14",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-04/get-your-renal-impairment-study-enrolled.pdf",
"encodingFormat": "application/pdf"
}
}
]
}